Price$1.36-0.10 (-6.85%)
01:30 PM07:45 PM
News · 26 weeks36+50%
2025-12-142026-06-07
Mix2190d
- SEC Filings8(38%)
- Other6(29%)
- Earnings3(14%)
- Offering2(10%)
- Analyst1(5%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 6-K filed by Nyxoah SA6-K - Nyxoah SA (0001857190) (Filer)
- SECSEC Form 424B5 filed by Nyxoah SA424B5 - Nyxoah SA (0001857190) (Filer)
- SECSEC Form FWP filed by Nyxoah SAFWP - Nyxoah SA (0001857190) (Subject)
- PRNyxoah Announces Pricing of $95 Million Underwritten Public OfferingINSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Pricing of $95 Million Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 5, 2026, 5:25 pm CET / 11:25 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, of 55,232,558 of its ordinary shares at an offering price of $1.72 (EUR 1.48) per share, b
- SECSEC Form 6-K filed by Nyxoah SA6-K - Nyxoah SA (0001857190) (Filer)
- SECSEC Form 424B5 filed by Nyxoah SA424B5 - Nyxoah SA (0001857190) (Filer)
- PRNyxoah Announces Proposed Offering of Ordinary SharesINSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Proposed Offering of Ordinary Shares Mont-Saint-Guibert, Belgium – June 4, 2026, 10:02 pm CET / 4:02 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union. All of the ordinary shares are being offered by Nyxoah and there are no selling sharehold
- PRNyxoah Enters New Chapter of Long Term Value CreationINSIDE INFORMATION REGULATED INFORMATION Nyxoah Enters New Chapter of Long Term Value Creation Commencement of process to transition to a U.S.-based CEOTransition to support further acceleration of commercial Genio launch in the United States Mont-Saint-Guibert, Belgium – June 4, 2026, 10:01 pm CET / 4:01 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the commencement of a leadership transition process in order to further accelerate the Company's U.S. commercial traction. Following seven successful years leading Nyxoah, Olivier Taelm
- PRInformation on the total number of voting rights and sharesREGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 20, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 1,031,323 new shares on May 20, 2026 in connection with the contribution in kind of a receivable held by the holder of the convertible bonds issued by the Company on December 18, 2025. For more information on this transaction, please refer to the special report of the board of directors dated May 19, 20261. Share capital: EUR 6,521,361.42
- SECSEC Form 6-K filed by Nyxoah SA6-K - Nyxoah SA (0001857190) (Filer)
- PRNyxoah Reports First Quarter 2026 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio reimbursement in the U.S. Mont-Saint-Guibert, Belgium – May 12, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2026. Q1 2026 Financial and Operating Highlights Financials U.S. net revenue first quarter 2026 was €4
- ANALYSTNyxoah S.A. downgraded by Stifel with a new price targetStifel downgraded Nyxoah S.A. from Buy to Hold and set a new price target of $5.00
- PRInvitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 10, 2026REGULATED INFORMATIONMay 8, 2026, 10:05pm CET / 4:05pm ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 10, 2026 The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders' meeting of the Company, to be held on Wednesday, June 10, 2026 at 2:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time. The annual shareholders' meeting will be followed immediately by an extraordinary shareholders' meeting. The C
- PRNyxoah to Participate in the Bank of America 2026 Healthcare ConferenceNyxoah to Participate in the Bank of America 2026 Healthcare Conference Mont-Saint-Guibert, Belgium – April 30, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Bank of America 2026 Healthcare Conference on Wednesday, May 13th, 2026. The Company is scheduled to present at 5:15pm Eastern Time the same day via webcast. A live audio webcast of Nyxoah's presentation at the conference can be accessed through this LINK. The Company will be avai
- PRNyxoah to Release First Quarter 2026 Financial Results on May 12, 2026Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026 Mont-Saint-Guibert, Belgium – April 28, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2026 on Tuesday, May 12, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q1 20
- SECSEC Form S-8 filed by Nyxoah SAS-8 - Nyxoah SA (0001857190) (Filer)
- SECSEC Form 20-F filed by Nyxoah SA20-F - Nyxoah SA (0001857190) (Filer)
- PRPublication relating to transparency notificationsREGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Robert Taub / Robelga SRL On March 19, 2026, Nyxoah received a transparency notification from Robert Taub and related person Robelga SRL, following the crossing above the 3% threshold by Robelga SRL on December 30, 2025 (while the overall "group" participation did not change). Based on the notification, Robert Taub (together with his
- SECSEC Form 6-K filed by Nyxoah SA6-K - Nyxoah SA (0001857190) (Filer)
- PRNyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsREGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of SalesFoundation Established to Drive Significant Growth in 2026 Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025. Recent Financial and Operating Highlights Fourth quarter gross revenue of €6
- PRPublication relating to transparency notificationREGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), March 13, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BNP Paribas Asset Management On March 11, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA. Based on the notification, BNP Paribas Asset Management Europe SAS holds 1,307,817 voting rights, representing 3.00% of the total number of voting rights on March 9, 2026 (43,662,403). The notification da
- PRNyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services ConferenceNyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 11, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, which takes place March 16 – 19, 2026. Olivier Taelman, Nyxoah's Chief Executive Officer, will deliver a corporate presentation on Monday, March 16, 2026, at 8:40 am ET. A webcast of the presen
- PRNyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or
- PRPublication relating to transparency notificationsREGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), February 27, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Robert Taub / BMI Estate On February 26, 2026, Nyxoah received a transparency notification from Robert Taub and related person BMI Estate, following the passive crossing of a threshold. Based on the notification, Robert Taub (together with his controlled undertakings) holds 4,360,800 voting rights, consisting of 4,310,800 voting r
- PRInformation on the total number of voting rights and sharesREGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares on February 20, 2026. Share capital: EUR 6,511,048.19 Total number of securities carrying voting rights: 43,662,403 (all ordinary shares) Total number of voting rights (= denominator): 43,662,403 (all relating to ordinary shares)Number of rights to subscribe to securities carrying voting rights not yet issued: 3,416,319 (all g
NYXH FAQ
7 questionsWhat does Nyxoah SA do?
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.Where does NYXH stock trade?
Nyxoah SA (NYXH) is listed on NASDAQ.What sector and industry is NYXH in?
Nyxoah SA operates in the Health Care sector, Medical/Dental Instruments industry.When did Nyxoah SA go public?
Nyxoah SA (NYXH) completed its IPO in 2021.What are analysts saying about NYXH?
Nyxoah SA has had 8 recent analyst actions on file. The most recent action was from Stifel: Hold with a $500.00 price target on 2026-05-12.What companies are similar to NYXH?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare NYXH side-by-side with any of them on Quantisnow.How can I track NYXH on Quantisnow?
Quantisnow aggregates Nyxoah SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NYXH to receive live email and push alerts on every new disclosure.